Van Hulzen Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Van Hulzen Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-90	Closed	-$64.1K	–	912
2024 Q4	$64.1K	Buy	+90	New	+$75.5K	﹤0.01%	463
2021 Q4	–	Sell	-360	Closed	-$218K	–	315
2021 Q3	$218K	Sell	360 -100	-22%	-$62.1K	0.03%	247
2021 Q2	$257K	Hold	460	–	–	0.04%	223
2021 Q1	$218K	Hold	460	–	–	0.03%	238
2020 Q4	$222K	Sell	460 -60	-12%	-$32.4K	0.03%	255
2020 Q3	$291K	Buy	520 +140	+37%	+$84.9K	0.04%	197
2020 Q2	$237K	Buy	+380	New	+$216K	0.04%	221

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Van Hulzen Asset Management's REGN Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 90 shares — an estimated $64.1K sold.

Van Hulzen Asset Management first reported a position in REGN in Q2 2020 and held it in 7 quarters. The position peaked at $291K in Q3 2020. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Van Hulzen Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Van Hulzen Asset Management sold 90 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $64.1K.
Van Hulzen Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Van Hulzen Asset Management's Regeneron Pharmaceuticals position peaked at $291K in Q3 2020.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.